阳离子转运蛋白2基因A270S位点多态性与万古霉素致急性肾损伤的相关性研究

发布时间：2018-01-14 09:14

本文关键词：阳离子转运蛋白2基因A270S位点多态性与万古霉素致急性肾损伤的相关性研究　出处：《中国临床药理学杂志》2017年23期 　论文类型：期刊论文

【摘要】：目的探讨阳离子转运蛋白2(OCT2)基因位点A270S(rs316019)不同基因型与成年人使用万古霉素造成急性肾损伤(AKI)的关系。方法选择114例使用万古霉素的中国汉族患者,根据疗程中是否出现AKI,将其分为AKI组(35例)和无AKI组(79例)。抽取患者外周静脉血,选用限制性片段长度多态性方法检测OCT2A270S基因多态性,用Logistic回归分析考察AKI的风险因素。结果 A270S基因型分布符合Hardy-Weinberg平衡(P0.05)。AKI组A270S GG、GT和TT基因型患者分别为26例(74.29%),8例(22.89%)和1例(2.82%),无AKI组A270S GG、GT和TT基因型患者分别为72例(91.94%),6例(7.59%)和1例(0.47%),差异均有统计学意义(均P0.05)。Logistic回归结果显示,年龄、体重指数和A270S基因多态性均为万古霉素导致AKI的风险因素(均P0.05)。结论患者年龄、体重指数和A270S基因多态性可能与万古霉素导致的AKI有关。
[Abstract]:Objective to investigate the genotypes of cationic transporter 2OCT2 (A270Srs316019) and the acute renal injury induced by vancomycin in adults (A270Srs316019). Methods 114 Chinese Han patients who received vancomycin were selected. According to whether or not AKI appeared in the course of treatment, the patients were divided into two groups: AKI group (n = 35) and no AKI group (n = 79). Peripheral venous blood was extracted from the patients. Restriction fragment length polymorphism (RFLP) was used to detect the polymorphism of OCT2A270S gene. Logistic regression analysis was used to study the risk factors of AKI. Results the genotype distribution of A270S was consistent with that of Hardy-Weinberg equilibrium (P0.05). A270S GG in AKI group. The numbers of GT and TT genotype were 26 / 74.29 and 8 / 22.89, respectively) and 1 / 2 / 82 / 2, respectively. There was no A270S GG in AKI group. There were 72 patients with GT genotype and 6 patients with TT genotype (n = 6) and one patient with TT genotype (n = 1). The difference was statistically significant (all P0.05. logistic regression results showed that age. Body mass index (BMI) and A270S gene polymorphism were the risk factors of vancomycin induced AKI (all P 0.05). BMI and A 270S gene polymorphism may be associated with vancomycin induced AKI.
【作者单位】：北京大学第一医院药剂科;北京大学药学院药事管理与临床药学系;北京大学第一医院肾内科;
【分类号】：R969
【正文快照】： 杨莉1b(1.北京大学第一医院,a.药剂科;b.肾内科,北京100034;2.北京大学药学院药事管理与临床药学系,北京100191)MA Ling-yun1a,2,ZHOU Ying1a,XIANG Qian1a,HU Kun1a,MA Ling-yue1a,YANG Ting1a,CHEN Chao-yang1a,GAO Fei-fei1a,2,CUI Yi-min1a,YANG Li1b(1.a.Department of P

【相似文献】